key: cord-0885375-xr5pbyp5
authors: Huang, Chanyan; Soleimani, Jalal; Herasevich, Svetlana; Pinevich, Yuliya; Pennington, Kelly M.; Dong, Yue; Pickering, Brian W.; Barwise, Amelia K.
title: Clinical Characteristics, Treatment, and Outcomes of Critically Ill Patients With COVID-19: A Scoping Review
date: 2020-10-26
journal: Mayo Clin Proc
DOI: 10.1016/j.mayocp.2020.10.022
sha: dbf36a506d483ba9ed1ba710ee4c546ad0be57cf
doc_id: 885375
cord_uid: xr5pbyp5

A growing number of studies on coronavirus disease 2019 (COVID-19) are becoming available, but a synthesis of available data focusing on the critically ill population has not been conducted. We performed a scoping review to synthesize clinical characteristics, treatment, and clinical outcomes among critically ill patients with COVID-19. Between 1/1/2020 and 5/15/2020, we identified high-quality clinical studies describing critically ill patients with a sample size >20 patients by performing daily searches of the World Health Organization and LitCovid databases on COVID-19. Two reviewers independently reviewed all abstracts (2785 unique articles), full-text (218 articles), and abstracted data (92 studies). 92 studies were included, including 61 from Asia, 16 from Europe, 10 from North and South America, as well as 5 multinational studies. Notable similarities among critically ill populations across all regions included a higher proportion of older males infected and with severe illness, high frequency of co-morbidities (hypertension, diabetes, and cardiovascular disease), abnormal chest imaging findings, and death secondary to respiratory failure. Differences in regions included newly identified complications (e.g., pulmonary embolism) and epidemiologic risk factors (e.g., obesity), less chest computed tomography imaging performed, and increased use of invasive mechanical ventilation (70-100% vs. 15-47% of ICU patients) in Europe and the US compared to Asia. Future research directions should include proof-of-mechanism studies to better understand organ injuries and large-scale collaborative clinical studies to evaluate the efficacy and safety of antivirals, antibiotics, IL-6 receptor blockers, and interferon. The current established predictive models require further verification in other regions outside China.

Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), causing coronavirus disease 2019 , is the novel coronavirus first detected in Wuhan, China in December 2019, 1,2 that continues to spread globally with more than 13 million cases confirmed as of July 15, 2020 (https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9e cf6). The clinical spectrum of COVID-19 ranges widely from asymptomatic infection to critical illness with a high risk of mortality. [3] [4] [5] Based on the evidence to date, there is a high probability of requirement for intensive care unit (ICU) level of care among patients with COVID-19, leading to a substantial increase in the demand for critical care beds. Understanding the disease trajectory and those most likely to benefit from critical care will be vital for ICU clinicians as they grapple with this new illness and understand how best to manage patients within potentially resource-constrained settings.

Since there are limited antiviral treatment options for COVID-19 patients and the severity of disease is closely related to the prognosis, 4 it is also essential to triage COVID-19 patients and identify early from among the many mild cases the few that will progress to critical illness, to effectively prioritize resources for patients with the highest risk, keep them under continuous close monitoring and intervene as needed to prevent the progression of disease.

As a growing body of literature on COVID-19 is becoming available, a small number of systematic and scoping reviews have been published since February 2020. However, because of the relatively short time-lapse since the outbreak of this novel disease, most reviews have either focused on a single aspect of COVID-19 (e.g., imaging findings, 6 co-morbidities, 7 J o u r n a l P r e -p r o o f 6 treatment 8 ) or included a very limited number of studies with minimal quantitative data synthesis, 9 or primarily described disease features among the general population, 10 and often included studies from one single country. 11,12 Initial research emerged from Asia, but more COVID-19 studies from Europe and North America have now been published. What is missing from the current literature, however, is a synthesis of the worldwide literature on critically ill patients specifically. Given the urgency of the COVID-19 epidemic and the need to understand information about critically ill patients suffering from COVID-19, a scoping review was considered suitable and useful for mapping the available evidence to identify knowledge gaps. 13 This study had several objectives. Firstly, we wanted to synthesize the current and emerging literature describing the clinical features, treatment, and outcomes, as well as risk factors associated with poor prognosis among critically ill patients with COVID-19 during the early months of the pandemic. Secondly, we wanted to provide frontline clinicians with insights for the effective management of severely ill patients with COVID-19. Finally, we aimed to identify knowledge gaps to guide future research endeavors. 8 exclusion are reported in the PRISMA flowchart. During the process of gathering and reviewing information, we modified the inclusion and exclusion criteria as new ideas emerged and ensured that the previous steps complied with the change in protocol.

Data abstraction on each of the included articles was performed by two independent reviewers (CH, JS, SH, YP, or KP) using a tailored Excel form, which was piloted beforehand.

Data abstracted included the following: literature characteristics (e.g., journal, publication date, title, first author), characteristics related to study method (e.g., article type, study design, country of the study conducted, sample size, subgroups divided), variables related to patient clinical characteristics (e.g., demographics, co-morbidities, symptoms, laboratory finding, imaging assessments, the severity of illness), interventions (e.g., drug treatments, oxygen supplies, mechanical ventilation), clinical outcomes (e.g., discharge, the severity of the disease, mortality, length of stay in hospital), risk factors associated with severity of illness or prognosis as identified using multivariate analysis, and key findings. As the data extraction process unfolded, we also enhanced the data extraction form, with new or more precise categories as needed. Reviewers also had regular meetings to address any challenges and to ensure concordance with their abstraction methods.

The literature search generated 3172 records. Of these, 387 were duplicates and 2567 were excluded. A full-text review was conducted on 218 studies. One additional relevant RCT study was included for data synthesis. A total of 92 studies were included for data abstraction. Table 1 summarizes the main characteristics of the included literature. 59% of studies were original articles and 35% were research letters. Study designs were primarily retrospective observational studies (90%), followed by RCTs (6%) and prospective observational studies (4%).

Nearly half of them were multi-center studies. Geographically, the articles largely originated in Asian countries (66%), followed by European countries (17%), American countries (11%), and multinational regions (6%). The sample size ranged from 20 to 44,672 patients, with over onehalf of the studies including more than 100 subjects. 30% of studies analyzed a full cohort and the other studies included one or two subgroups of critically ill patients with COVID-19. The definition of what constituted critically illness varied in the studies, characterized as patients admitted to the ICU (25%), 3,16-37 severe COVID-19 defined by Chinese guidelines (27%) 38-62 or American Thoracic Society guidelines (3%), 63-65 those suffering from an organ injury or dysfunction (25%), 66-88 and those who died from COVID-19 (20%). 4, [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] 

The main clinical characteristics and outcomes from 52 studies of critically ill patients with COVID-19 are summarized in Patients with severe COVID-19 had more prominent laboratory abnormalities including lymphocytopenia and leukopenia disease, 63 and exhibited a significant drop of T lymphocyte subset counts (CD3+, CD4+, CD8+ T-cell), which was associated with a higher risk of mortality. 60 Evidence of inflammatory cytokine abnormalities (TNF-α, IL-1, and IL-6) was notable, 49 with increased IL-6 recorded in 87% of severe cases. 57 The establishment of an inflammatory state as demonstrated by elevated C-reactive protein (CRP) levels was also noted in 76-100% of critically ill patients, 55,57,58,64,85,105 and the median concentration of CRP was nearly 10-fold higher than mildly-ill patients. 60 Procalcitonin elevation indicating an inflammatory response was observed in 14-47% of severe disease, 55,57,58,63 75% of ICU patients 23 and 34-100% of non-survivors 16, 89, 97 in Chinese studies, but only in 25% of patients receiving IMV in the US. 72 Dramatic elevation of D-Dimer values was found in 50-87% of critically ill cases in China, 16 to be independently associated with hospital mortality and performed better to predict mortality in patients with COVID-19 compared with SOFA, and the score ≥17 served as an early warning indicator of death. 16 CRB-65 (Confusion, Respiratory rate, Blood pressure, Age 65 years and older) score was considered better to identify patients with COVID-19 at risk for intensive respiratory or vasopressor support than the quick sepsis-related organ failure assessment (qSOFA) score. 74 It appeared that patients in the US and Europe had a longer stay in ICU compared with patients in China (9-18 days 18,28,31,33,36 vs. 7-9 days 44 ). There is wide variability in case-fatality ratios among critically ill patients, partially because of differences in length of follow-up. For example, in two studies, the reported mortality was 7% and 8%, respectively, with 89% still (Table 2) Characteristics of pharmacological treatment for severe COVID-19 are displayed in Table   3 .

Antivirals were provided to 44-100% of critically ill patients in Asia and Europe. 3,23,25-treatment for clinical improvement or reducing mortality. 83 Three studies have focused on the efficacy and safety of remdesivir therapy among severely ill patients with COVID-19. 54,75,79 One early RCT in China found remdesivir did not provide significant clinical or antiviral effects. 54 However, recently, preliminary results of an ongoing multinational RCT showed that the 10-day course of remdesivir was superior to placebo in shortening the median time to recovery (11 vs.

15 days) while adverse events did not increase. 79 A multinational prospective observation study also showed that 68% of severe COVID-19 treated with remdesivir had clinical improvement in oxygen-support status. 75 Of note, the US did not rely on the antiviral agent in the initial phases of the pandemic (only in 4-29% of critical cases 36,72,84 ), preferring hydroxychloroquine in approximately 90% of critically ill patients with COVID-19. 36,84 Two observational studies involving large samples in the US showed that treatment with hydroxychloroquine was not associated with reduced in-hospital mortality or intubation. 76,88 Furthermore, adverse events among patients receiving hydroxychloroquine were common, including arrhythmia, QT prolongation, and even cardiac arrest. It is reported that QTc intervals increased by 93% of ICU patients after hydroxychloroquine therapy. 17 The phase IIb RCT of chloroquine diphosphate in severe COVID-19 in Brazil found no improved mortality outcomes from chloroquine. 29 Despite no concurrent observed bacterial infection, antibacterial therapy among severe COVID-19 was widely used in China (43-100%), 3 It appeared that US hospitals were less likely to use corticosteroids, even in those receiving IMV. 21,36,72 Studies showed that methylprednisolone treatment might be beneficial for COVID-severe cases did not delay viral clearance. 53 Immunoglobulin is also commonly applied as an adjuvant treatment in up to 75% of critically ill cases in Asian countries. 25 

Thirty-one studies explore risk factors related to clinical prognosis using multivariate methods, mainly with logistic regression models (42%) and Cox proportional hazards models (35%). In total over 50 risk factors were found to be associated with disease severity or worse outcomes, including factors related to demographics, symptoms, co-morbidities, complications, laboratory, chest imaging, severity scores assessment, and treatment (Table 4) . Among these studies, advanced age (defined as >65 years old in most studies) was the most frequent to be identified as an independent factor (n=18), followed by elevated lactate dehydrogenase (LDH) (n=6), male sex (n=5), hypoxia (n=5), lymphopenia (n=5) and presence of any co-morbidity (n=4), hypertension (n=4) and increased CRP (n=4). Furthermore, antiviral treatment (lopinavir/ritonavir 200/50 mg plus hydroxychloroquine 200 mg twice a day) was shown to be one of the predictors for lower odds of discharge from hospital for COVID-19 in an Italian study. 71 Moreover, six clinical or laboratory models were developed to predict COVID-19 progression or in-hospital mortality in China, and some of them were validated in patients from centers (Table 4) . 51, 61, 64, 77, 93 

In this scoping review, we have synthesized the emerging global evidence on critically ill patients with COVID-19, specifically clinical characteristics, treatment, and risk factors associated with poor prognosis. This review aimed to provide insights for effective management of severe COVID-19 and identify gaps in knowledge to guide future research.

Some clinical findings were similar for all regions, for example, the frequency of ARDS. However, some of the findings differed by region, likely due to different patient population characteristics, medical resources, and management strategies. These comparative analyses are helpful for frontline providers to guide our understanding of the disease and what patient and population characteristics may be more influential in determining clinical outcomes, thereby guiding decision making about care intensity.

Globally, older patients are more likely to progress to critical illness, which may be associated with a higher frequency of co-morbidities or age-related immune dysfunctions resulting from low-grade chronic inflammation. 23 Most studies found that male patients were more susceptible to developing critical illness or death than females potentially because of the protection of X chromosome and sex hormones, which play an essential role in innate and adaptive immunity. 106 In our scoping review, two studies that documented race and ethnicity in the US reported that race/ethnicity did not relate to the severity of COVID-19. 72, 84 Of note, outside the US, how race and ethnicity are classified differs to the US approach making assumptions from the demographic data included in our scoping review challenging and inconclusive. In recent months, however, notable disparities in outcomes for racial and ethnic minorities in the US and J o u r n a l P r e -p r o o f the UK have become apparent when the information has been accurately collected (https://www.nytimes.com/2020/07/08/health/coronavirus-risk-factors.html). 107, 108 Clinical manifestations are similar in all countries. Frontline clinicians should be aware of the possible neurological involvement of SARS-CoV-2 for critically ill patients 19,34,65 and some atypical extra-pulmonary symptoms such as gastrointestinal manifestation, which may lead to diagnostic delay. 44 Of note, only 74% of refractory patients presented with fever on admission (significantly lower than general patients) and fever was shown to be a protective factor for recovery, suggesting that patients with a slow or meager response to the virus were more likely to have severe disease. 85 Elevated LDH and lymphopenia were frequently identified as markers of severity. A meta-analysis study supported these findings. 12

These similar patterns of age or sex differences in COVID-19 patient severity or mortality and similar clinical manifestations in different countries allow us to map the global epidemiology of the disease.

Notably, there is variation in co-existing chronic medical conditions geographically, indicating that prediction models from Asia may not be reliable in the US and Europe, where the impact of other risk factors such as obesity on disease severity should be thoroughly explored. For example, when compared to multiple Asian studies, European and the US populations receiving IMV were more likely to have obesity, 72 a risk factor for worse prognosis in patients with COVID-19. 109 Given the prevalence of obesity and the association between obesity and decreased pulmonary function, these findings are not surprising.

The presence of hypertension is thought to be an independent risk factor for poor prognosis. 39,51,56,93 It is unclear if this association is related to the pathogenesis of hypertension J o u r n a l P r e -p r o o f or antihypertensive treatment. Angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) were identified to be associated with cardiac injury, 66 but some other studies showed that chronic ACEIs/ARBs use was not associated with worse outcomes. 110, 111 These associations should be considered with extreme caution as the studies have not been adjusted for age, co-morbidities, or other confounding variables. Currently, clinical data supports continuing to follow existing professional society guidelines and not discontinue ACEIs/ARBs in the setting of the COVID-19 pandemic. 38, 112, 113 Using the markers for early identification of severe COVID-19 may help providers prioritize the need to provide aggressive therapeutics and guide clinical management. This is critically important for risk stratification for optimal resource allocation, particularly in settings with limited critical care resources. Remarkably, several studies evaluating risk factors used univariate analysis instead of multivariate analysis, and thus the conclusions should be interpreted with caution. A systematic review on risk factors for severe COVID-19 was conducted, but all the included studies were retrospective studies from China and thus cannot necessarily be applied to patients worldwide. 12 Unlike that work, 12 this scoping review includes high-quality studies that evaluated potential risk factors of illness severity or poor prognosis in multivariate models.

The higher incidence of PE in critically ill patients with COVID-19 in European countries may be associated with the prevalence of obesity in the patient-group. 35 Increased D-dimer suggesting hypercoagulability is a nonspecific biomarker in COVID-19 patients. In patients with limited disease but requiring supplementary oxygen, an additional contrast-enhanced CT should be performed to rule out PE per the European Society of Radiology and the European Society of J o u r n a l P r e -p r o o f Thoracic Imaging guidelines. 114 Or if the severity of respiratory failure cannot be explained by the current unenhanced CT findings, CT pulmonary angiographies (CTPA) should be considered (European Society of Cardiology). 115 Clinicians should recognize that those with COVID-19 are a high-risk population and therefore consideration of early thromboprophylaxis is essential. 31

The comparisons of clinical outcomes should be interpreted with caution as criteria for hospitalization, ICU admission, discharge, and healthcare infrastructures are likely to be different between countries. The case-fatality ratios of severe COVID-19 vary across regions and in different time points, mainly because of differences in testing approaches and capacity (in some regions, patients with mild disease were not tested, resulting in a higher case-fatality ratio). Other contributors to outcomes differences include characteristics of the healthcare system infrastructure (mortality rate were higher in health systems with fewer medical resources and limited access to critical care resources), the impact of policies changing over time (implementation of physical distancing measures and testing speed), as well as accuracy in reporting total cases and mechanisms for representing mortality from COVID-19 (in data calculated the mortality for mechanically ventilated from New York, the denominators excluded people who were still in the ICU on a ventilator 104 ).

We should note that during the early outbreaks in some regions such as Wuhan and New York, inadequate capacity in the health system may have contributed to the high rate of mortality of mechanically ventilated patients. In South Korea where medical resources were adequate with a small outbreak, it was observed that 30-day mortality in mechanically ventilated patients with COVID-19 was 25%, similar to those with seasonal influenza-related respiratory failure. 27 Additionally, patients in the US and Europe appeared to be older, and J o u r n a l P r e -p r o o f 20 sicker indicated by higher APACHE II and SOFA scores as well as longer ICU LOS than Asian patients, and this may have contributed to the higher mortality.

Management of acute respiratory failure is the key to the treatment of seriously ill patients. Studies from China showed that for patients with ARDS or extensive pulmonary effusion on CT, HFNC or NIMV was recommended to maintain PEEP and prevent alveolar collapse even among patients who did not have refractory hypoxemia. 116 As recent data from the international from the VIRUS COVID-19 Registry (https://sccmcovid19.org/) indicates, neither HFNC nor NIMV (15% and 11% of hospitalized patients, respectively) were adopted frequently in the other 17 countries. However, currently, there is still no evidence to demonstrate whether patients would benefit more from NIMV or early-intubation strategy. The use of corticosteroid to reduce possible immune-mediated organ damage remains controversial since higher doses were associated with a higher subsequent plasma viral load in Severe Acute Respiratory Syndrome (SARS) patients. 118 Although observational studies in China showed potential benefits for COVID-19 patients, 53,80 these must be carefully balanced against risks. We can see that the US and Europe did not adopt them as often as China. Fortunately, a preliminary, unpublished analysis from a multi-center RCT in the United Kingdom showed that dexamethasone (6 mg once per day) reduced mortality by up to one third in hospitalized patients with severe respiratory complications of COVID-19. 119 Globally, very few studies mentioned a specific indication for the use of antibiotics, and rates of secondary bacterial infections reported in severe COVID-19 appear to be low. 3, 20, 25, 42, 46, 47, 60, 72 However, the use of broad-spectrum antimicrobial therapy was widely reported. The frequent prescription of empirical antimicrobials in patients with COVID-19 is worrisome due to potential increasing bacterial resistance. Additionally, there were no differences in mortality among those who did or did not receive antimicrobial drugs. 97

To our knowledge, this is the first scoping review focusing on critically ill patients with COVID-19 mapping the clinical characteristics, treatment, and risk factors associated with prognosis. At the beginning of the study, we consulted with a specialist librarian and confirmed that the WHO and LitCovid databases on COVID-19 were appropriate to capture the breadth of J o u r n a l P r e -p r o o f research on this novel topic. Furthermore, we focused on journals with an IF ≥5, so we could quickly review and synthesize high-quality studies.

This review has some limitations. First, it is possible that the use of additional literature databases, the involvement of journals with IF ≤5, and articles published in non-English would have yielded relevant articles giving us a more comprehensive understanding of critically ill patients with COVID-19. Second, a majority of COVID-19 patients were still hospitalized at the endpoint of studies, potentially causing inaccurate clinical outcomes and underestimating mortality. Third, many of the included studies were observational in nature and this may limit inferences that can be drawn from their findings. Fourth, disparities in outcomes for racial and ethnic minorities were not apparent based on our work, although this has become a fundamental aspect of critical illness outcomes in the US. 120, 121 Fifth, the vast differences in societal structures, healthcare systems, and policies made a globally valid report challenging, given that those with the worst performance were also likely to contribute the least published data. As COVID-19 continues to spread globally, the epidemiology as well as mortality and morbidity outcomes, may be changing based on improved management strategies and our understanding.

The review revealed several gaps in our knowledge of COVID-19 within critical illness.

Hypertension has been identified as a host risk factor for severe COVID-19 infection. There is an urgent need to fund scientific investments into advancing novel therapeutic interventions for SARS-CoV-2 infections. Promising signals from observational data must be rigorously confirmed in high-quality RCTs. Some studies have suggested that COVID-19 severity might be due to virus-activated inflammatory cytokine abnormalities, 48,49,52,57 leading to organ injuries. In the future, large-scale collaborative clinical studies, proof-of-mechanism studies, and autopsy studies are needed to better understand organ injuries. In the meantime, whether anticytokine therapies or immunomodulators such as IL-6 receptor blockers (e.g., tocilizumab and sarilumab) to control overactive cytokine response could be effective therapeutic drugs for COVID-19 requires further exploration. 48, 122 Given that a multi-center RCT showed that early antiviral therapy combined with interferon beta-1b was superior to antiviral drugs alone in shortening the duration of viral shedding and hospital stay in patients with non-severe COVID-19, 123 future studies should also consider focusing on the role of interferon in treatment. 

In this scoping review, we assessed the current evidence related to critically ill patients with COVID-19 to summarize the clinical manifestations, management, and risk factors associated with poor prognosis to inform clinicians and identify future research directions. Some early clinical research findings from China and Europe can be applied to US practice; however, there are notable differences in co-existing chronic disease, complications, and intervention strategies geographically as well as the application of predictive models. In the future, it would be useful to consider large adaptive platform trials to pool data for demonstrating efficacy and safety for novel treatments. J o u r n a l P r e -p r o o f 

A Novel Coronavirus from Patients with Pneumonia in China

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

COVID-19)

Coronavirus Disease 2019 (COVID-19): A Systematic Review of Imaging Findings in 919 Patients

Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis

Keep up with the latest coronavirus research

Acute Physiology and Chronic Health Evaluation II Score as a Predictor of Hospital Mortality in Patients of Coronavirus Disease

Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit

Baseline Characteristics and Outcomes of 1591

Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region

Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19

Prediction for Progression Risk in Patients with COVID-19

Pneumonia: the CALL Score

Remdesivir for the Treatment of Covid-19 -Preliminary Report

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia

ST-Elevation Myocardial Infarction in Patients With COVID-19: Clinical and Angiographic Outcomes

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

COVID-19 in solid organ transplant recipients: Initial report from the US epicenter

Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China

Acute Pulmonary Embolism Associated with COVID-19 Pneumonia Detected by Pulmonary CT Angiography

Well-aerated Lung on Admitting Chest CT to Predict Adverse Outcome in COVID-19 Pneumonia

Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State

15-day mortality and associated risk factors for first UK cohort

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

Clinicolaboratory study of 25 fatal cases of COVID-19 in Wuhan

Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up

Determining risk factors for mortality in liver transplant patients with COVID-19

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the

Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus Disease 2019 From a Nationwide Analysis in China

ImmGen report: sexual dimorphism in the immune system transcriptome

COVID-19 and African Americans

COVID-19 and Racial/Ethnic Disparities

Obesity and Outcomes in COVID-19: When an Epidemic and Pandemic Collide

Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19

Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19

Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019

Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19)

COVID-19 patients and the radiology departmentadvice from the European Society of Radiology (ESR) and the

ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19

Lower mortality of COVID-19 by early recognition and intervention: experience from Jiangsu Province

A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19

Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients

Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19

Accessed 16

Creating Real Change at Academic Medical Centers -How Social Movements Can Be Timely Catalysts

CKD 4-6%; 22,23,26 cancer 4-11%

Fatal cases Any

Up to 90% 91,99 : COPD 20-21%, diabetes 47-65%, hypertension 55-68%

Acute cardiac injury 8-31%(overall)

8% (patients receiving IMV)

19% with acute kidney failure (overall)

Acute liver injury 6-29% (overall)

14% (overall)

Pulmonary embolism NA 17-21% (overall) (France) 31

Sepsis 33-100% (fatal cases) 94,98 NA Shock 23-31% (overall)

Viral: 11% (fatal cases

Viral: 14% (overall)

Intervention HFNC 10-68% 23

NIMV 11-72% (overall) 3,23

ECMO 1-15% 3

Prone 4-12% 25